MDWD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
MediWound is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy, especially for someone unwilling to wait for a better entry. The stock has a mix of meaningful long-term upside from the BARDA contract and EscharEx pipeline, but the current setup is still weak technically and the near-term fundamentals remain pressured. I would not buy it today; holding off is the better call.
MDWD is in a short-term downtrend. MACD histogram is negative and worsening, moving averages are bearish with SMA_200 > SMA_20 > SMA_5, and price is trading below the pivot at 15.819 near support at 14.688. RSI_6 at 21.82 shows the stock is oversold, but oversold alone is not enough to reverse the trend. The pre-market price of 15.5 is still below the pivot and does not yet confirm a strong recovery. Based on the trend indicators, the current price action is weak and not an attractive immediate entry for a beginner long-term investor.
["10-year BARDA contract worth up to $197 million, which supports long-term revenue visibility", "Management reaffirmed 2026 revenue guidance of $24M-$26M", "Analysts still maintain Buy/Outperform ratings despite trimming price targets", "EscharEx is viewed by analysts as a potentially transformative long-term pipeline driver"]
["Q1 2026 revenue fell 62.5% year over year to about $1.5 million", "Revenue is still being hurt by limited NexoBrid capacity and timing of BARDA and Department of War grants", "One analyst said full-year revenue guidance may be at risk because it depends on BARDA timing", "Technical trend remains bearish with negative MACD and bearish moving averages", "No strong insider, hedge fund, politician, or congress trading support was reported"]
Latest quarter: Q1 2026. Revenue dropped sharply by 62.5% to $1.5 million, but the company reported a smaller loss than expected and GAAP EPS of -$0.23 beat expectations. Management reaffirmed full-year 2026 revenue guidance of $24M-$26M, but the quarter showed clear top-line weakness and dependency on grant timing. The key long-term positives are contract visibility and pipeline optionality, but current operating growth is still uneven.
Recent analyst trend is slightly more cautious on price targets but still constructive on the stock. Alliance Global lowered its target to $22 from $25 and kept a Buy rating, while Oppenheimer cut its target to $32 from $33 and maintained Outperform. The pros view is that BARDA support and EscharEx can drive long-term value. The cons view is that near-term revenue is soft, guidance depends heavily on grant timing, and the current quarter did not show strong operating momentum.
